TRLV · Trulieve Cannabis Corp.
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Retail dispensaries | 240 | Q1 2026 | — |
| Rewards program members | 1M | Q1 2026 | — |
| branded product units sold | 50.1M | Full Year 2025 | — |
| gross margin | 60% | Full Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TRLV
this stock
Trulieve Cannabis Corp.
|
$1.87B | +16.1% | -0.4% | — | 0.7% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.75B | +17.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$50.24B | +4.0% | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.41B | -2.4% | — | — | 0.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 18.2%
- Net QoQ
- +34.8M sh
- Top holder
- AdvisorShares Investments…
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TRLV | +10.8% | +16.4% | +55.2% | +16.7% | +16.1% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +11.2% | +13.5% | +43.7% | +13.7% | +3.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.